David Tuch is an Expert in Residence at the London Institute for Healthcare Engineering. David currently serves as an advisor at Lightpoint, Telix Pharmaceuticals Limited, Lucida Medical Ltd, OmioLabs, EnAcuity, LPM, and Stealth. Additionally, David is the Chairman and CEO of LPM. Tuch is also an aspiring author working on a biography of their British cousin who was a soldier of fortune in the 1950s-1970s. Furthermore, David is a member of the International Advisory Board at UCL, focusing on the Wellcome / EPSRC Centre for Interventional and Surgical Sciences. Tuch holds a PhD from the Harvard-MIT Division of Health Sciences and Technology, a BA in Physics from the University of Chicago, and has also completed a degree in Strategic Marketing Management from Harvard Business School.
This person is not in any teams
This person is not in any offices
London Institute for Healthcare Engineering
The London Institute for Healthcare Engineering (LIHE) at King's College London brings together world-class research and development expertise across academia, the NHS and MedTech companies all co-located within a landmark building overlooking the Thames and embedded within the St Thomas’ Hospital campus. Going beyond a typical accelerator, LIHE is the ground-breaking translation engine from medical technology innovation to clinical and commercial adoption within St Thomas’ Hospital campus, part of England’s leading NHS Trust for patient recruitment to clinical studies. Thus collocated, LIHE uniquely brings together King’s research excellence, GSTT's leading clinical practice and the MedTech sector’s commercial innovation power and talent, while simultaneously providing physical space in the heart of London to start-ups, SMEs and multinationals. Translation of innovative technologies into the NHS for therapy and diagnosis is complex and requires multidisciplinary teams (clinicians, physical scientists, engineers, industry, regulatory advisors, health economists, commercial). Many novel technologies fail due to poor understanding of the challenges surrounding clinical practice, manufacturing, diagnostic/treatment pathways, clinical adoption mechanisms, regulation, and the payer landscape. LIHE will ensure MedTech spin-outs and start-ups successfully overcome these hurdles by creating a unique, supportive ecosystem of all critical stakeholders. Our mission is to transform patient care by creating a seamless pipeline of MedTech innovation, from conception to commercialisation, enabling early NHS adoption of cutting-edge technology from King's, London, and across the UK. We will be launching our inaugural acceleration programme in 2024. If you are a MedTech spin-out, start-up, or are interested in making innovation a reality for the benefit of the NHS and of patients, come and speak to us!